SCHEMBL4336102

SCHEMBL4336102

[C](=C=Cc1ccccc1)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.39
ALDH1A1 P00352 3/20 0.36
TSHR P16473 2/20 0.36
MAOB P27338 2/20 0.36
CYP2A6 P11509 1/20 0.36
LMNA P02545 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
FFAR1 O14842 1/20 0.31
IDO1 P14902 2/20 0.31
GRIN2D O15399 2/20 0.31
GRIN3B O60391 2/20 0.31
GRIN1 Q05586 2/20 0.31
GRIN2A Q12879 2/20 0.31
GRIN2B Q13224 2/20 0.31
GRIN2C Q14957 2/20 0.31
GRIN3A Q8TCU5 2/20 0.31
TAAR1 Q96RJ0 1/20 0.31
NFE2L2 Q16236 1/20 0.31
CYP19A1 P11511 1/20 0.31
MAOA P21397 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL9795266 0.78 ALDH1A1 (0.43) ALDH1A1TSHRMAOBCYP2A6LMNA
SCHEMBL366631 0.75 ALDH1A1 (0.45) APPALDH1A1TSHRMAOBCYP2A6
SCHEMBL496414 0.74 APP (0.43) APPALDH1A1TSHRMAOBCYP2A6
SCHEMBL10492226 0.74 APP (0.43) APPALDH1A1TSHRMAOBCYP2A6
SCHEMBL339509 0.74 APP (0.43) APPALDH1A1TSHRMAOBCYP2A6
SCHEMBL1178413 0.72 ALDH1A1 (0.43) ALDH1A1TSHRMAOBCYP2A6LMNA
SCHEMBL4343899 0.72 APP (0.41) APPTSHRLMNAMAPTCYP1A2
SCHEMBL4333668 0.72 ALDH1A1 (0.38) ALDH1A1TSHRMAOBCYP2A6LMNA
SCHEMBL5701503 0.72 ALDH1A1 (0.43) ALDH1A1TSHRMAOBCYP2A6LMNA
Diphenylacetylene SCHEMBL339222 0.71 APP (0.60) APPALDH1A1TSHRLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4216713-B2 2009-01-28 JP claimed
EP-1404324-A4 PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF XENOPORT INC (US) 2004-12-22 EP claimed
JP-2004536873-A 2004-12-09 JP claimed
EP-1404324-A2 PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF Xenoport, Inc. (US) 2004-04-07 EP claimed
US-20030176398-A1 Prodrugs of GABA analogs, compositions and uses thereof HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT 2003-09-18 US claimed
WO-2002100347-A2 PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF XENOPORT, INC. (US) 2002-12-19 WO claimed
EP-2085087-A1 Prodrugs of gaba analogs, compositions and uses thereof Xenoport, Inc. (US) 2009-08-05 EP disclosed
EP-1902714-A1 Prodrugs of gaba analogs, compositions and uses thereof Xenoport, Inc. (US) 2008-03-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176398-A1 Prodrugs of GABA analogs, compositions and uses thereof GABRB1, GABRB2, GABRB3 APP 442/4885ALDH1A1 298/4885TSHR 2583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.